American Society for Clinical Pharmacology and Therapeutics
Clinical Pharmacology & Therapeutics (1999) 65, 118–118; doi:
The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhea.
Jean Brown RN1, Briggs W. Morrison MD2, Mark Bitner MD1, Carl Woolsey MD1, Michael Sandler2, Vickie Dunkley RN1, Paul Kotey PhD2 and Beth Seldenberg MD2
- 1Jean Brown Associates, Inc., Salt Lake City, UT.
- 2Merck & Co., Inc., Rahway, NJ.
